Neox is a privately-owned full-service clinical CRO with headquarters in Prague, Czech Republic.
We conduct clinical trials for pharmaceutical, biotechnology and medical device companies and other CROs throughout Europe, with a focus on Central and Eastern Europe (CEE). With more than 230 clinical research professionals in CEE countries, and 80 employees in partnering CROs, Neox is one of the largest Central and Eastern European CROs.
Neox is a full-service CRO offering clinical research services such as: biostatistics, clinical monitoring, data management, eCRF design, eDiaries, expert consultancy, drug safety, medical monitoring, medical writing, pharmacovigilance and safety, project management, quality assurance and audits, regulatory and ethics committee submissions, site contracting, study rescue, and training and education for Phase I-IV studies. We offer our services as a full-service package or individually as a tailored solution to meet your specific needs.
We are committed to maintaining the highest quality of work to our clients. Our standardised QA processes mean that we can promise sponsors that each research project is conducted ethically, in compliance with the protocol, relevant SOPs and ICH GCP. Clients can also be secure in the knowle and that the data collected is accurate and verifiable.
To provide continuous quality control, assurance and improvement, the main tools we use are:
Neox is your trusted partner for the entire clinical development process, offering strategic and therapeutic leadership, throughout the duration of your project.
Extensive Phase I-IV experience
We have Phase I-IV experience in a variety of therapeutic areas in almost all European countries.
Our regulatory managers work to guarantee that every aspect of the trial is correctly designed for regulatory approval.
From Phase I, all the way through to Phase IV, you can be feel safe in the knowledge that your study is performed under high-quality standards. Our therapeutic experts, project managers, and CRAs certify that your study will be running without delays in a cost-efficient way.
Neox is here to provide services at any stage of drug development in any European country. We aim to exceed your expectations.
High performance quality starts with clear standard procedures, detailing training processes for both onboarding and continuous training.
Specific role-based curricula are in place for all key job roles.
The training process includes:
The new-hire onboarding programme is led by a Neox trainer and internal speakers.
The theoretical part of the training is followed by a practical on-site monitoring training specific for CRAs.
Training on relevant Neox SOPs is completed by each Neox employee. Training on sponsor SOPs, systems and project-specific trainings are provided according to sponsor instructions.
Therapeutic area and investigational product trainings are typically provided by the Neox medical director, if agreed by the sponsor. For periodical advanced training, both internal and external speakers may be invited.
Quality of service is also supervised through periodical on-site co-monitoring visits and internal audits.
Years of clinical research experience, understanding local requirements and established relationships with investigators, ensures that your trial will always be performed in an optimal setting for high patient enrolment.
Neox operates in Austria, Bulgaria, the Czech Republic, Finland, Germany, Hungary, Poland, Romania, Slovakia, Sweden, Switzerland and the United Kingdom. In other European countries we operate through our partners.
The total population of the Central and Eastern European region exceeds 300million, providing access to a large pool of potential clinical trial subjects. The healthcare systems in the CEE region are highly centralised, as most patients are referred to major centres where they always visit the same doctor. This results in a strong personal relationship between patients and their doctors. These factors have an additional positive impact on data quality through better patient compliance, faster and easier patient enrolment and lower dropout rates even in long-term trials.
With Neox you will experience rapid enrolment and you will have access to leading, highly motivated investigators. Although investigator fees in Central and Eastern European region are increasing and falling into line with those of Western Europe, the overall costs in the CEE region still remain lower due to faster patient recruitment, a larger number of enrolled patients, and high quality of data resulting in lower data query rates.
Please see our contact details below for further information.